Consulting Solutions for Startup and Early Stage Cell and Gene Therapy Companies
About Labyrinth
Labyrinth reflects the myriad of needs, pathways, and challenges within the cell and gene therapy space. Like a true labyrinth, this field is intricate, dynamic, and sometimes disorienting — where innovators often struggle to find the most efficient route forward.
At Labyrinth CGT Consulting, the name signifies more than complexity: it symbolizes guidance through that complexity. We help clients:
Align science, business, and investors so therapies reach patients faster.
Create clarity in strategic messaging for investor and community buy in.
Navigate manufacturing scale-up.
Closing the gaps to bring CGT therapies to more patients isn’t just our tagline — it’s our compass within the labyrinth.
Stuart Gibb, Ph.D.
Founder, Labyrinth CGT Consulting, LLC
For over 20 years I’ve worked across startups, mid-sized biotechs, and global CGT device manufacturers — I’ve been in the trenches, built the teams, and now help both Biotechs and Investors assemble the right tools to accelerate their cell therapy ambitions.
Over the years, I’ve built a career at the intersection of science, manufacturing, and business development — tackling the challenges of cell therapy manufacturing, GMP-grade bioreactors, and commercialization. I’ve helped bridge the gap between breakthrough innovation and scalable, patient-focused solutions.
Today, as Founder of Labyrinth CGT Consulting, LLC, I partner with early-stage biotech teams and investors to close critical gaps, stay lean, and maximize value creation — providing strategic messaging, manufacturing guidance, and objective scientific and market analysis to turn vision into execution and product commercialization.
— Stuart Gibb, Ph.D
